A.F. GABDRAKHMANOVA¹, R.F. GAYNUTDINOVA², L.F. AZNABAEVA¹, G.Sh. ABIZGILDINA³, S.A. KURBANOV⁴

¹Bashkir State Medical University, 3 Lenin Str., Ufa, Russian Federation, 450008

²Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

³Duplex med LLC, 103A Artema Str., Sterlitamak, Russian Federation, 453100

⁴City Clinical Hospital №10, 47 Koltsevaya Str., Ufa, Russian Federation, 450112

  Gabdrakhmanova A.F. ― D. Med. Sc., Professor of the Ophthalmology Department with a course of Institute of additional vocational education, tel. (347) 275-97-65, e-mail: aniya2005@yandex.ru

Gaynutdinova R.F. ― Cand. Med. Sc., Associate Professor of the Ophthalmology Department, tel. (843) 528-09-14, e-mail: rg_dinova@list.ru

Aznabaeva L.F. ― D. Med. Sc., Professor of the Otorhinolaryngology Department with a course of Institute of additional vocational education, tel. (347) 251-03-39, e-mail: rg_dinova@list.ru

Kurbanov S.A. ― Cand. Med. Sc., Ophthalmologist of the Eye Microsurgery Department №2, tel. (347) 242-72-14, e-mail: srbek@mail.ru

Abizgildina G.Sh. ― Cand. Med. Sc., Ophthalmologist, tel. (3473) 23-98-98

In order to study the correlation between specific biochemical markers of neurotrophic and neurodegeneration in patients with primary open-angle glaucoma on the background of neuroprotective therapy, a tear fluid was studied in 23 patients (46 eyes) with primary open-angle glaucoma of the second and third stages, the average age of which is 66.3±10.8 years. For monitoring, a group of healthy individuals was recruited. Along with local antihypertensive therapy in comprehensive treatment of patients with POAG, a complex of peptides isolated from retinas of cattle ― Retinalamin^® (GEROPHARM LLC, St. Petersburg) №10 was intramuscularly injected at a dose of 5 mg a day. Before and after treatment in tear fluid, the concentration of a neurotrophic brain marker (brain-derived neurotrophic factor or BDNF) and a neurodegeneration protein — neuron specific enolase (neuron specific enolase or NSE) was localized through the enzyme-linked immunosorbent assay (ELISA) with subsequent calculation of their ratio BDNF/NSE. As a result of the research, it was concluded that with POAG there is a change in the level of the neurotrophic factor of the brain and a marker of neurodegeneration ― neuron-specific enolase in a tear fluid with respect to the control towards the prevalence of neurodegeneration markers in 38% of patients with stage II and in 45% in stage III of the disease. After the use of Retinalamin^® in the complex therapy for patients with stage II of POAG, a decrease in initially high concentrations of BDNF/NSE in the SS to the values of the control group was noted. The ratio of neuronal markers of neurotrophy and neurodegeneration reflects the possibilities of compensatory-adaptive and pathological reaction of the eye in conditions of glaucomatous process.

Key words: primary open-angle glaucoma, tear fluid, brain-derived neurotrophic factor, neural-specific enolase, Retinalamin^®.

REFERENCES

1. Glaukoma. Natsionalʹnoe rukovodstvo, pod red. E.A. Egorova [Glaucoma. National leadership. Ed. by E.A. Egorov]. Moscow: GEHOTAR-Media, 2013.
2. Egorov E.A., Egorov A.E., Brezhnev A.Yu. Sovremennye aspekty neyroprotektornoy terapii glaukomy [Modern aspects of neuroprotective therapy of glaucoma]. Moscow: Aprelʹ, 2014.
3. Erichev V.P., Tumanov V.P., Panyushkina L.A. Glaucoma and neurodegenerative disease. Glaukoma, 2012, 1, pp. 62-68 (in Russ.).
4. Kamenskikh T.G., Zakharova N.B., Kolbenev I.O. et al. Investigation of molecular mechanisms of apoptosis regulation of retinal ganglion cells in primary open-angle glaucoma. RMZH. Klinicheskaya oftalʹmologiya, 2013, 2, pp. 46-51 (in Russ.).
5. Kurysheva N.I. Neyroprotektsiya i neyroregeneratsiya: perspektivy v lechenii glaukomy [Neuroprotection and neuroregeneration: perspectives in the treatment of glaucoma]. FGBOU IPK FMBA Rossii. Moscow, 2014.
6. Gabdrakhmanova A.F., Kurbanov S.A., Kunafina E.R. Some aspects of the complex treatment of open-angle glaucoma. Meditsinskiy Vestnik Bashkortostana, 2014, 9 (2), pp. 42-45 (in Russ.).
7. Gabdrakhmanova A.F., Kurbanov S.A. The first results of assessing the quality of life of patients with glaucoma in the Republic of Bashkortostan. Rossiyskiy oftalʹmologicheskiy zhurnal, 2013, 6 (2), pp. 16-19 (in Russ.).
8. Aznabaev B.M., Gabdrakhmanova A.F., Gallyamova G.R., Aleksandrov A.A. Features of hemodynamics of the eye in diabetic retinopathy. Meditsinskiy vestnik Bashkortostana, 2013, 8 (4), pp. 21-24 (in Russ.).
9. Kamilov Kh.M., Kasimova M.S., Khamraeva G.Kh. A specific marker of neurodegeneration in the diagnosis of optic neuritis. Oftalʹmologiya, 2015, 12 (2), pp. 25-30 (in Russ.).
10. Kharintsev V.V., Serkin D.M., Serebryakova O.V. et al. The role of neuron-specific enolase in the course of endocrine ophthalmopathy and the formation of optical neuropathy. Klinicheskaya i ehksperimentalʹnaya tireoidologiya, 2015, 11 (4), pp. 31-35 (in Russ.).
11. Iuvone P., Boatright J., Tosini G., Ye K. N-acetylserotonin: circadian activation of the BDNF receptor and neuroprotection in the retina and brain. Adv. Exp. Med. Biol, 2014, 801, pp. 765-71. doi: https://doi.org/10.1007/978-1-4614-3209-896
12. Ji J., Elyaman W., Yip H. et al. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Eur. J. Neurosci, 2004, 19 (2), pp. 265-72. https://doi.org/10.1111/j.0953-816X.2003.03107.x